According to the set timeline, Persomed will reach its first major milestone in the middle of next year: a proof of concept and phase I clinical study for at least eight patients. In 2023, the consortium will conduct therapies on a larger group of selected patients.

 

When everything goes according to plan, the vaccine will be ready to apply for official registration for wide deployment. At that time, the cell therapy methodology can also be extrapolated to other forms of cancer.